Literature DB >> 18725437

Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

G L Drusano1, Olanrewaju O Okusanya, Adedoyin Okusanya, Brian Van Scoy, D L Brown, Robert Kulawy, Fritz Sörgel, Henry S Heine, Arnold Louie.   

Abstract

Sixty days of ciprofloxacin administration at 500 mg every 12 h is currently recommended for the prophylaxis of inhalational exposure to Bacillus anthracis. We examined Bacillus anthracis (Delta-Sterne strain) in our hollow-fiber infection model. We measured the ciprofloxacin concentrations achieved and the number of organisms present before heat shock (total population) and after heat shock (spore population). We fit a mathematical model to these data. Monte Carlo simulation with differing initial spore burdens (3, 5, and 6.9 log(10) CFU/ml) demonstrated that 35 days of this regimen would completely clear the spore burden in 95% of patients. Durations of 110 days did not achieve 99.9% eradication, irrespective of initial burden, because of between-patient variance in drug pharmacokinetics. Given the absence of person-to-person transmission for Bacillus anthracis, adverse drug effects with long-term ciprofloxacin administration, and the possibility of engendering resistance in bodily flora, shorter prophylaxis duration should be given consideration, along with careful monitoring of all exposed individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725437      PMCID: PMC2573157          DOI: 10.1128/AAC.00453-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Medical counterbioterrorism: the response to provide anthrax prophylaxis to New York City US Postal Service employees.

Authors:  Robert Partridge; John Alexander; Tom Lawrence; Selim Suner
Journal:  Ann Emerg Med       Date:  2003-04       Impact factor: 5.721

2.  Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Robert Bollinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

3.  Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Authors:  Mark R Deziel; Henry Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 4.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

5.  Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.

Authors:  Henry S Heine; Jennifer Bassett; Lynda Miller; Justin M Hartings; Bruce E Ivins; M Louise Pitt; David Fritz; Sarah L Norris; W Russell Byrne
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

6.  Project BioShield: what it is, why it is needed, and its accomplishments so far.

Authors:  Philip K Russell
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

7.  Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001.

Authors:  Mariaelena D Jefferds; Kayla Laserson; Alicia M Fry; Sharon Roy; James Hayslett; Laurence Grummer-Strawn; Laura Kettel-Khan; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

Review 8.  An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001.

Authors:  Susan Blank; Linda C Moskin; Jane R Zucker
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

  8 in total
  5 in total

1.  Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Authors:  Arnold Louie; Brian D VanScoy; David L Brown; Robert W Kulawy; Henry S Heine; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

2.  Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Authors:  Sha Cao; Aizhen Guo; Ziduo Liu; Yadi Tan; Gaobing Wu; Chengcai Zhang; Yaxing Zhao; Huanchun Chen
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

3.  Quantitative models of the dose-response and time course of inhalational anthrax in humans.

Authors:  Damon J A Toth; Adi V Gundlapalli; Wiley A Schell; Kenneth Bulmahn; Thomas E Walton; Christopher W Woods; Catherine Coghill; Frank Gallegos; Matthew H Samore; Frederick R Adler
Journal:  PLoS Pathog       Date:  2013-08-15       Impact factor: 6.823

4.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03

5.  Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.

Authors:  Brent J Yamamoto; Annette M Shadiack; Sarah Carpenter; Daniel Sanford; Lisa N Henning; Nestor Gonzales; Edward O'Connor; Leslie S Casey; Natalya V Serbina
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.